Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Vincenzi

Showing results (1-10 of 411) with videos related to

Pageof 42
Sort By:
Current Cancer Drug Targets|March 17, 2010
Hot topic: biology in anticancer treatmentBruno Vincenzi
British Journal of Cancer|February 23, 2019
Secondary KIT mutations: the GIST of drug resistance and sensitivityAndrea Napolitano, Bruno Vincenzi
Ebiomedicine|February 10, 2019
PDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?Andrea Napolitano, Bruno Vincenzi
Women'S Health (London, England)|October 7, 2009
Taxanes in adjuvant chemotherapy for early breast cancerBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|May 14, 2008
Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesiumBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetronGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Women'S Health (London, England)|October 7, 2009
Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?Daniele Santini, Bruno Vincenzi, Giuseppe Tonini
Nature Clinical Practice. Oncology|May 1, 2008
Updated follow-up of patients treated with bortezomib for relapsed multiple myelomaDaniele Santini, Bruno Vincenzi, Giuseppe Tonini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Thymidylate synthase expression in colorectal cancer: the never-ending storyBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|March 10, 2011
Bisphosphonate anticancer activityGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Pageof 42

Showing results (1-10 of 411) with videos related to

Sort By:
Pageof 42
Current Cancer Drug Targets|March 17, 2010
Hot topic: biology in anticancer treatmentBruno Vincenzi
British Journal of Cancer|February 23, 2019
Secondary KIT mutations: the GIST of drug resistance and sensitivityAndrea Napolitano, Bruno Vincenzi
Ebiomedicine|February 10, 2019
PDGFRα inhibition in soft-tissue sarcomas: Have we gotten it all wrong?Andrea Napolitano, Bruno Vincenzi
Women'S Health (London, England)|October 7, 2009
Taxanes in adjuvant chemotherapy for early breast cancerBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|May 14, 2008
Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesiumBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Drug Metabolism & Toxicology|August 23, 2006
New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetronGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Women'S Health (London, England)|October 7, 2009
Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?Daniele Santini, Bruno Vincenzi, Giuseppe Tonini
Nature Clinical Practice. Oncology|May 1, 2008
Updated follow-up of patients treated with bortezomib for relapsed multiple myelomaDaniele Santini, Bruno Vincenzi, Giuseppe Tonini
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Thymidylate synthase expression in colorectal cancer: the never-ending storyBruno Vincenzi, Daniele Santini, Giuseppe Tonini
Expert Opinion on Pharmacotherapy|March 10, 2011
Bisphosphonate anticancer activityGiuseppe Tonini, Bruno Vincenzi, Daniele Santini
Pageof 42